Sildenafil Tablet
Product Images NDC 71610-679

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 71610-679). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 100 mg (71610 0675 02)

Label for Sildenafil, USP 100 mg oral tablets, containing 2 tablets per package. The label includes the NDC number 71610-0675-02 and storage instructions to keep the product between 20-25 degrees Celsius, protect from light, and keep out of reach of children. The labeler is Aphena Pharma Solutions - Tennessee, LLC, located in Cookeville, TN.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Figure 1 (Sildenafil 1)

Chemical structure of Sildenafil showing its molecular components including aromatic rings and functional groups, represented in a two-dimensional line drawing format.*

FDA Label Image

Figure 2 (Sildenafil 2)

A line graph comparing systolic blood pressure (mmHg) over 24 hours post dose between sildenafil 100 mg and placebo. The x-axis shows time in hours post dose, and the y-axis shows changes in systolic blood pressure, with two lines representing sildenafil and placebo groups.*

FDA Label Image

Figure 3 (Sildenafil 3)

A line graph displaying the change in systolic blood pressure (SBP) over time postdose (hours) for two groups: Doxazosin + Placebo and Doxazosin + Sildenafil 25 mg. The x-axis represents time in hours up to 8 hours, and the y-axis shows SBP change in mmHg, ranging from -40 to 20. The graph illustrates fluctuations in SBP changes for both groups throughout the time period.*

FDA Label Image

Figure 4 (Sildenafil 4)

A line graph showing the change in EBP (mmHg) over time postdose (hours) comparing two treatments: Doxazosin + Placebo and Doxazosin + Sildenafil 50 mg. The graph plots EBP changes from 0 to 8 hours, illustrating different response trends for each treatment group.*

FDA Label Image

Figure 5 (Sildenafil 5)

A line graph titled 'Mean Standing Systolic Blood Pressure Change from Baseline' showing blood pressure change (mmHg) over time (hours) after dosing. Two lines compare the effects of Doxazosin combined with Sildenafil 100 mg versus Doxazosin with placebo over an 8-hour period.*

FDA Label Image

Figure 6 (Sildenafil 6)

Line graph showing plasma concentration of sildenafil (ng/mL) over time post dose (hours) comparing commercial tablet treatment. Concentration peaks sharply around 1 hour and declines progressively to near zero by 24 hours.*

FDA Label Image

Figure 7 (Sildenafil 7)

Two bar graphs depicting the effect of SILDENAFIL tablets and placebo on maintenance of erection by baseline score. The upper graph shows percentages of patients at endpoint across baseline scores 0 to 5 for SILDENAFIL, with higher percentages in higher baseline scores. The lower graph shows the same data for placebo, with more variability and lower percentages overall.*

FDA Label Image

Figure 8 (Sildenafil 8)

A bar chart comparing the percentage of patients reporting improvement across different treatment groups: placebo, and sildenafil tablets at 25 mg, 50 mg, and 100 mg doses. The chart shows increasing improvement percentages with higher sildenafil doses, with the 100 mg group having the highest percentage reporting improvement.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.